Journal of Nuclear Medicine: 57 (5)

May 1, 2016; Volume 57,Issue 5

Cover image

Immuno-PET imaging of a CA125-targeting ⁸⁹Zr-labeled antibody may enhance the evaluation of high-grade serous ovarian cancer and provide a roadmap for surgery. See page 771.

In this issue

Issue highlights

Molecular Imaging Approaches for Supplemental Screening in Women at Increased Breast Cancer Risk
Comparing the Diagnostic Potential of ⁶⁸Ga-Alfatide II and ¹⁸F-FDG in Differentiating Between Non–Small Cell Lung Cancer and Tuberculosis
Repeatability of Quantitative ¹⁸F-Fluoromethylcholine PET/CT Studies in Prostate Cancer
Prospective Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to